Cargando…

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics

Pictilisib, a weakly basic compound, is an orally administered, potent, and selective pan‐inhibitor of phosphatidylinositol 3‐kinases for oncology indications. To investigate the significance of high‐fat food and gastric pH on pictilisib pharmacokinetics (PK) and enable label recommendations, a dedi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Tong, Fraczkiewicz, Grazyna, Salphati, Laurent, Budha, Nageshwar, Dalziel, Gena, Smelick, Gillian S., Morrissey, Kari M., Davis, John D., Jin, Jin Y., Ware, Joseph A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702897/ https://www.ncbi.nlm.nih.gov/pubmed/28748626 http://dx.doi.org/10.1002/psp4.12228

Ejemplares similares

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
por: Schöffski, Patrick, et al.
Publicado: (2018)

(11)C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging
por: Han, Na, et al.
Publicado: (2019)

GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway
por: Chen, Haifeng, et al.
Publicado: (2022)

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy
por: Ehrhardt, Michael, et al.
Publicado: (2014)

Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941
por: Mehraj, Umar, et al.
Publicado: (2022)

The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells
por: Nováková, Jana, et al.
Publicado: (2019)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
por: Usman, Muhammad Waqas, et al.
Publicado: (2018)

The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor
por: Tzeng, Huey-En, et al.
Publicado: (2015)

Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
por: Usman, Muhammad Waqas, et al.
Publicado: (2019)

The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
por: Ehrhardt, Michael, et al.
Publicado: (2018)

Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics
por: Kikuchi, Hugh, et al.
Publicado: (2023)

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
por: Wang, Lingfei, et al.
Publicado: (2017)

A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer
por: Khalafi, Shayan, et al.
Publicado: (2021)

GDC respond to crisis
Publicado: (2020)

Mentoring, performance and the GDC
por: Saw, Mabel, et al.
Publicado: (2021)

GDC announces new chair
Publicado: (2021)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
por: Nayak-Kapoor, Asha, et al.
Publicado: (2018)

NLO QCD corrections to top anti-top bottom anti-bottom production at the LHC
por: Bredenstein, Axel, et al.
Publicado: (2010)

Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice
por: Deinhardt-Emmer, Stefanie, et al.
Publicado: (2021)

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
por: Heffron, Timothy P., et al.
Publicado: (2016)

GDC 2: Compression of large collections of genomes
por: Deorowicz, Sebastian, et al.
Publicado: (2015)

GDC publishes 2019 fitness to practise statistics
Publicado: (2020)

GDC statement on complaints during the pandemic welcomed
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

Search for top and bottom squarks
por: Rott, Carsten
Publicado: (2003)

Top (and Bottom) asymmetries at the LHC
por: Pinamonti, Michele
Publicado: (2015)

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
por: Song, Kyung W., et al.
Publicado: (2022)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

GDC and CQC issue statement on life-support training
Publicado: (2020)

Fermilab: Physics from top to bottom
Publicado: (1987)

Masses and structures of bottom and top mesons
por: Akano, M
Publicado: (1994)

Top-bottom doublet in the sphaleron background
por: Moreno, J M, et al.
Publicado: (1995)

Search for Top and Bottom squarks at CMS
por: Hooberman, Benjamin
Publicado: (2013)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

NLO QCD corrections to top anti-top bottom anti-bottom production at the LHC: 2. full hadronic results
por: Bredenstein, Axel, et al.
Publicado: (2010)

GDC highlights importance of clear public safety COVID information
Publicado: (2020)

Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway
por: Liang, Chao, et al.
Publicado: (2021)

Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer
por: Cheng, Wei-Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5vjsnce9mrj6be81kf1j5h8frc